

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Heidi Lopez de Diego et al.	Confirmation No.:	6471
Serial No.:	10/568,572	Group Art Unit:	1614
Filed:	August 14, 2006	Examiner:	TBA
For:	Succinate and Malonate Salts of [Trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine] and Use as a Medicament		

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Date: February 16, 2010

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with the duty of disclosure under 37 C.F.R. § 1.56, transmitted herewith is a Supplemental Information Disclosure Statement (SIDS) in connection with the above-identified patent application. This SIDS complies with the requirements under 37 C.F.R. § 1.98 and is being submitted pursuant to 37 C.F.R. § 1.97(b), wherein the SIDS is being offered with a Request for Continued Examination (RCE) under § 1.114, before the mailing date of a first Office Action on the merits for the patent application. Accordingly, Applicants believe no fee is required for submission of this SIDS. However, the Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to Deposit Account No. 503201.

A copy of the PTO/SB/08 Form(s), as considered and initialed by the Examiner, is kindly requested to be returned with the next office communication.

Respectfully submitted,

Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 261-1331 Ext. 790

/Margaret M. Buck Reg. No. 54,010/

Margaret M. Buck, Esq.
Registration No. 54,010